HighTower Advisors LLC Takes Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)

HighTower Advisors LLC bought a new position in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 29,922 shares of the company's stock, valued at approximately $472,000.

Other institutional investors also recently modified their holdings of the company. POM Investment Strategies LLC boosted its holdings in Dr. Reddy's Laboratories by 400.0% in the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock valued at $36,000 after purchasing an additional 1,820 shares during the period. Independence Bank of Kentucky increased its stake in Dr. Reddy's Laboratories by 400.0% during the 4th quarter. Independence Bank of Kentucky now owns 2,775 shares of the company's stock worth $44,000 after acquiring an additional 2,220 shares during the period. Allworth Financial LP raised its holdings in Dr. Reddy's Laboratories by 447.8% in the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company's stock valued at $41,000 after acquiring an additional 2,230 shares in the last quarter. Glenmede Trust Co. NA bought a new stake in shares of Dr. Reddy's Laboratories during the 3rd quarter valued at $207,000. Finally, Sierra Ocean LLC acquired a new stake in shares of Dr. Reddy's Laboratories during the 4th quarter worth $43,000. Institutional investors own 3.85% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Nomura downgraded shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th. StockNews.com downgraded shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a report on Friday, December 6th.

Remove Ads

Dr. Reddy's Laboratories Price Performance

NYSE:RDY traded down $0.03 during trading hours on Tuesday, hitting $13.17. The company's stock had a trading volume of 1,501,164 shares, compared to its average volume of 1,324,412. Dr. Reddy's Laboratories Limited has a twelve month low of $12.50 and a twelve month high of $16.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The stock has a fifty day simple moving average of $13.45 and a 200-day simple moving average of $14.58. The company has a market capitalization of $10.99 billion, a P/E ratio of 20.96 and a beta of 0.48.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, analysts anticipate that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.